Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo

Journal of Radiation Research

Volumn 46, Issue 4, 2005, Pages 453-459

  Sugie, Chikao ^a   Shibamoto, Yuta ^a   Ito, Masato ^a   Ogino, Hiroyuki ^a   Suzuki, Hiromasa ^a   Uto, Yoshihiro ^b   Nagasawa, Hideko ^b   Hori, Hitoshi ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Hypoxic radiosensitizers; KU 2285; Nimorazole; Sanazole

Indexed keywords

CELLS; CYTOLOGY; INDIUM COMPOUNDS; MAMMALS;

AEROBIC CONDITION; HYPOXIC RADIOSENSITIZER; IN-VITRO; KU-2285; NIMORAZOLE; NITROIMIDAZOLES; RADIOSENSITIZERS; SANAZOLE; SENSITISER; VITRO AND IN VIVO;

TUMORS;

EID: 33144465516     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.46.453     Document Type: Article

References (35)

1. 2 peaks of a murine fibrosarcoma between carbon-ion and X-ray irradiation. J. Radiat. Res. 45: 303-308.
2. Liu, J., Qu, R., Ogura, M., Shibata, T., Harada, H. and Hiraoka, M. (2005) Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J. Radiat. Res. 46: 93-102.
3. Horsman, M. R. (1998) Measurement of tumor oxygenation. Int. J. Radiat. Oncol. Biol. Phys. 42: 701-704.
4. Adams, G. E., Kasan, N. M. and Joiner, M. C. (1997) Radiation, hypoxia and genetic stimulation: implications for future therapies. Radiother. Oncol. 44: 101-109.
5. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U. and Vaupel P. (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, Cancer Res. 56: 4509-4515.
6. Brizel DM., Scully SP., Harrelson JM., Layfield LJ., Bean JM., Prosnitz LR. and Dewhirst MW. (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma, Cancer Res. 56: 941-943.
7. Overgaard, J., Hansen, H. S., Andersen, A. P., Hjelm-Hansen, M., Jorgensen, K., Sandberg, E., Berthelsen, A., Hammer, R. and Pedersen, M. (1989) Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int. J. Radiat. Oncol. Biol. Phys. 16: 1065-1068.
8. Murayama, C., Suzuki, A., Sato, C., Tanabe, Y., Miyata, Y., Shoji, T., Suzuki, T., Sakaguchi, M. and Mori, T. (1992) Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration. Int. J. Radiat. Oncol. Biol. Phys. 22: 557-560.
9. Murayama, C., Suzuki, A., Sato, C., Tanabe, Y., Shoji, T., Miyata, Y., Nishio, A., Suzuki, T., Sakaguchi, M. and Mori, T. (1993) Radiosensitization by a new potent nucleoside analog: 1-(1',3',4'-trihydroxy-2'-butoxy)methyl-2- nitroimidazole (RP-343). Int. J. Radiat. Oncol. Biol. Phys. 26: 433-443.
10. Eschwege, F., Sancho-Garnier, H., Chassagne, D., Brisgand, D., Guerra, M., Malaise, E.P., Bey, P., Busutti, L., Cionini, L., N'Guyen, T., Romanini, A., Chavaudra, J. and Hill, C. (1997) Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 39: 275-281.
11. Overgaard, J., Hansen, H. S., Overgaard, M., Bastholt, L., Berthelsen, A., Specht, L., Lindelov, B. and Jorgensen K. (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother. Oncol. 46: 135-146.
12. Shibamoto, Y., Takahashi, M. and Abe, M. (1996) A Phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy. Radiother. Oncol. 40: 55-58.
13. Shibamoto, Y., Ohshio, G., Hosotani, R., Nishimura, Y., Manabe, T., Imamura, M. and Abe, M. (1997) A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy. Brit. J. Cancer. 76: 1474-1479.
14. Brown JM. (1995) Hypoxic cell radiosensitizers: the end of an era? Regarding Lee et al., IJROBP 32: 567-576
15. 1995. Int. J. Radiat. Oncol. Biol. Phys. 32: 883-885.
16. Shibamoto, Y., Sugie, C., Ito, M. and Ogino, H. (2004) The Japanese experiences with hypoxia-targeting pharmacoradio-therapy: from hypoxic cell sensitisers to radiation-activated prodrugs. Expert Opin. Pharmacother. 5: 2459-2467.
17. Shibamoto, Y., Nishimoto, S., Shimokawa, K., Hisanaga, Y., Zhou, L., Wang, J., Sasai, K., Takahashi, M., Abe, M. and Kagiya, T. (1989) Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys. 16: 1045-1048.
18. Sasai, K., Nishimoto, S., Shimokawa, K., Hisanaga, Y., Kitakabu, Y., Shibamoto, Y., Zhou, L., Wang, J., Takahashi, M., Kagiya, T. and Abe, M. (1991) A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys. 20: 1249-1254.
19. Sasai, K., Fushiki, M., Yukawa, Y., Suyama, S., Iwai, H., Shibamoto, Y., Nishimoto, S., Takahashi, M. and Abe, M. (1991) In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation. Int. T. Radiat. Oncol. Biol. Phys. 21: 1231-1234.
20. Oya, N., Shibamoto, Y., Sasai, K., Sugiyama, T. and Abe, M. (1993) In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses. Int. J. Radiat. Oncol. Biol. Phys. 27: 1113-1119.
21. Sasai, K., Iwai, H., Yoshizawa, T., Nishimoto, S., Shibamoto, Y., Kitakabu, Y., Oya, N., Takahashi, M. and Abe, M. (1992) Pharmacokinetics of fluorinated 2-nitroimidazole hypoxic cell radiosensitizers in murine peripheral nervous tissue. Int. J. Radiat. Biol. 62: 221-227.
22. Nemoto, K., Shibamoto, Y., Ohmagari, J., Baba, Y., Ebe, K., Ariga, H., Takai, Y., Ouchi, A., Sasai, K., Shinozaki, M., Tsujitani, M., Sakaguchi, M., Yamada, S. and Sakamoto, K. (2001) Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy. Anti-Cancer Drugs. 12: 1-6.
23. Sunamura, M., Karasawa, K., Okamoto, A., Ogata, Y., Nemoto, K., Hosotani, R., Nishimura, Y., Matsui, K., Matsuno, S. (2004) Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer. Pancreas. 28: 330-334.
24. Zeman E. M. (2000) Biologic basis of radiation oncology. In: Clinical Radiation Oncology, Eds. L. L. Gunderson and J. E. Tepper, pp. 1-41, Churchill Livingstone, New York, Edinburgh, London, Philadelphia.
25. Overgaard, J., Overgaard, M., Nielsen, O. S., Pedersen, A. K. and Timothy, A. R. (1982) A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Brit. J. Cancer. 46: 904-911.
26. Shibamoto, Y., Sakano, K., Kimura, R., Nishidai, T., Nishimoto, S., Ono, K., Kagiya, T. and Abe, M. (1986) Radiosensitization in vitro and in vivo by 3-nitrotriazoles. Int. J. Radiat. Oncol. Biol. Phys. 12: 1063-1066.
27. Rajagopalan, R., Kagiya, T. V. and Nair, C. K. (2003) Radiosensitizer sanazole (AK-2123) enhances gamma-radiation-induced apoptosis in murine fibrosarcoma. J. Radiat. Res. 44: 359-365.
28. Pasupathy, K., Nair, C. K. and Kagiya, T. V. (2001) Effect of a hypoxic radiosensitizer, AK 2123 (Sanazole), on yeast Saccharomyces cerevisiae. J. Radiat. Res. 42: 217-227.
29. Das T., Chakraborty S., Banerjee S., Mukherjee A., Samuel G., Sarma HD., Nair CK., Kagiya VT., Venkatesh M. (2004) Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. Bioorg. Med. Chem. 12: 6077-6084.
30. Alam A., Rapthap CC., Singha LI., Sharan RN., Singh V. (2005) Radiomodulatory effect of liposome encapsulated AK-2123 on tumor in mice exposed to hepatocarcinogen. Mol. Chem. Biochem. 271: 139-150.
31. Huan LC., Hua BY. (1994) Clinical pharmacokinetic study and sensitive effect of AK-2123. Int. J. Radiat. Oncol Biol Phys. 29: 607-610.
32. Huilgol, N. G., Chatterjee, N. and Mehta, A. R. (1996) An overview of the initial experience with AK-2123 as a hypoxic cell sensitizer with radiation in the treatment of advanced head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 34: 1121-1124.
33. Shibamoto, Y., Nishimoto, S., Mi, F., Sasai, K., Kagiya, T. and Abe, M. (1987) Evaluation of various types of new hypoxic cell sensitizers using the EMT6 single cell - spheroid - solid tumor system. Int. J. Radiat. Biol. 52: 347-357.
34. Adams, G. E., Flockhart, I. R., Smithen, C. E., Stratford, I. J., Wardman, P., Watts, M. E. (1976) Electron-affinic sensitization VII. A correlation between structures, one-electron reduction potentials and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat. Res. 67: 9-20.
35. Onishi, H., Araki, T., Shirato, H., Nagata, Y., Hiraoka, M., Gomi, K., Yamashita, T., Niibe, Y., Karasawa, K., Hayakawa, K., Takai, Y., Kimura, T., Hirokawa, Y., Takeda, A., Ouchi, A., Hareyama, M., Kokubo, M., Hara, R., Itami, J. and Yamada, K. (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 101: 1623-1631.